SCHEDULE: Octagon Capital Discloses 6.1% Stake in Dianthus Therapeutics

Octagon Capital Advisors LP and its affiliates, including Ting Jia, have reported a 6.1% beneficial ownership stake in Dianthus Therapeutics, Inc. common stock.

Summary

• Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP, Octagon Private Opportunities Fund II LP, and Ting Jia, collectively reported beneficial ownership of Dianthus Therapeutics, Inc. common stock.
• The aggregate amount beneficially owned by Octagon Capital Advisors LP and Ting Jia is 2,416,667 shares, representing 6.1% of the class.
• Octagon Investments Master Fund LP beneficially owns 2,125,000 shares, or 5.3% of the class.
• Octagon Private Opportunities Fund II LP beneficially owns 291,667 shares, or 0.7% of the class.
• The ownership percentages are calculated based on 39,804,361 common shares outstanding following Dianthus Therapeutics' underwritten public offering that closed on September 11, 2025, including the full exercise of the underwriter's option.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Dianthus Therapeutics.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm like Octagon Capital Advisors LP in Dianthus Therapeutics is generally viewed positively, as it signals institutional confidence in the company. The statement that the shares are held in the ordinary course of business and not for control purposes further supports a stable investment perspective.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, has disclosed a substantial stake in Dianthus Therapeutics, indicating confidence in the company's prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist play.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.1% stake may instill confidence among existing and potential shareholders, potentially stabilizing or positively influencing the stock price.
• Company Management: The presence of a large, non-activist institutional investor can provide a degree of stability and validation for the company's current strategy and management.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant, non-activist stake by Octagon Capital Advisors LP in Dianthus Therapeutics. While the presence of a substantial institutional investor can be a positive signal, this filing alone does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a factual ownership position. Investors should 'hold' and await further financial reports or strategic updates from Dianthus Therapeutics to make a more informed decision, using this ownership disclosure as one data point among many.

Keywords

Dianthus Therapeutics, Octagon Capital Advisors, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Ting Jia, Investment Fund